LYEL Stock Summary and Trading Ideas (Lyell Immunopharma | NASDAQ:LYEL)

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Lyell Immunopharma trades on the NASDAQ stock market under the symbol LYEL.

As of September 21, 2026, LYEL stock price declined to $10.93 with 140,619 million shares trading.

LYEL has a beta of 2.46, meaning it tends to be more sensitive to market movements. LYEL has a correlation of 0.11 to the broad based SPY ETF.

LYEL has a market cap of $267.83 million. This is considered a Small Cap stock.

Last quarter Lyell Immunopharma reported $4,000 in Revenue and -$1.92 earnings per share. This fell short of revenue expectation by $-600 and exceeded earnings estimates by $.08.

In the last 3 years, LYEL traded as high as $65.11 and as low as $7.65.

The top ETF exchange traded funds that LYEL belongs to (by Net Assets): VTI, IWM, VXF, SCHA, IWN.

LYEL has underperformed the market in the last year with a price return of -13.5% while the SPY ETF gained +18.5%. LYEL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -14.2% and -23.9%, respectively, while the SPY returned +3.8% and +0.7%, respectively.

LYEL support price is $10.50 and resistance is $11.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LYEL shares will trade within this expected range on the day.